Pharma Focus Asia

Merck Invests US$715 million in New Facility at Madison,USA

Introduction:
Merck with an investment of US$715 million plans for the expansion of Antibody-drug Conjugates (ADC) manufacturing. The new manufacturing facility will be located in Madison, Wisconsin, USA.

Features:
Antibody-drug Conjugates (ADC) manufacturing facility will be designed with an area covering 6,500-square-meter. This new facility will be engaged in the production of high-potent active pharmaceutical ingredients (HPAPI) and ADC manufacturing capabilities.

The project designed with a large area will be one of the largest manufacturing facilities to manage single-digit nanogram occupational exposure limit materials and support the continuous flow manufacturing of HPAPIs. Moreover, the new facility will be an addition to the first commercial ADC facility in North America specialised in ADC bio-conjugation, active pharmaceutical ingredients, excipient and adjuvants manufacturing.

The completion of the project is scheduled to be in the mid of 2022 and is expected to create 50 full-time jobs in the starting of 2021.

Specifications:

NameMerck
TypeExpansion
BudgetUS$715 million
YearMid-2022

 

Latest Issue
Get instant
access to our latest e-book
MFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Gibco Adherent Kidney Media PanelCPHI Korea 2024Equinix accelerated medical research...CHEMICAL INDONESIA 2024Thermofisher - Antibody Therapeutic PolishingINALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024
Searching for an end-to-end patient tech solution?